OWL-EVO1

DIAGNOSTIC_TEST2 trials

Sponsors

Owlstone Ltd

Conditions

Lung Cancer

Phase 1

Safety and Dose Ranging Study for OWL-EVO1 as a Lung Cancer EVOC® Probe (Evolution)

CompletedNCT05510674

Owlstone LtdLung Cancer

Start: 2021-07-06End: 2023-09-20Updated: 2023-12-20

Phase 2

Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe (Evolution Phase 2)

CompletedNCT06193239

Owlstone LtdLung Cancer

Start: 2023-10-05End: 2025-05-29Updated: 2026-07-09